- Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically
- Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59
- FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically
- FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83
- Bruker initiates FY26 guidance:
- Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2%
- Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind
BILLERICA, Mass.--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025.
Frank H. Laukien, Bruker’s President and CEO, commented: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second half of the year, as well improvements in semiconductor orders enabled our Scientific Instruments segment to achieve a book-to-bill ratio greater than 1.0x for the second quarter in a row, while our BEST segment booked strong multi-year orders.”
